[Article in German]
Jahn E, Sausele T. This e-mail address is being protected from spambots. You need JavaScript enabled to view it
The GLP-1-receptor-agonist liraglutide (Victoza) has been approved for the treatment of diabetes mellitus type 2 in Europe. Liraglutide is the first human GLP-1 analogue which is applied once a day. Efficacy and safety of liraglutide were investigated in the broad LEAD-study-programme in comparison with placebo and other common therapeutics for the treatment of diabetes mellitus type 2. Liraglutide has been approved for the combination with metformin and/or a sulfonylurea or with metformin and a thiazolidinedione, if treatment with one or a combination of these drugs is not sufficient for an adequate blood glucose control.
PMID: 19947303
| < Prev |
|---|
